Barclays’s AYTU BioPharma AYTU Stock Holding History

Barclays’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$108	Buy	+50	New	+$118	﹤0.01%	5187
2025 Q4	–	Sell	-1	Closed	-$2	–	5246
2025 Q3	$2	Hold	1	–	–	﹤0.01%	5429
2025 Q2	$2	Hold	1	–	–	﹤0.01%	5182
2025 Q1	$1	Buy	+1	New	+$1	﹤0.01%	5223
2023 Q1	–	Hold	0	–	–	–	5084
2022 Q4	–	Hold	0	–	–	–	5267
2022 Q3	–	Hold	0	–	–	–	4781
2022 Q2	–	Hold	0	–	–	–	5018
2022 Q1	–	Hold	0	–	–	–	4943
2020 Q4	–	Sell	-53	Closed	-$12K	–	4867
2020 Q3	$12K	Sell	53 -10	-16%	-$2.57K	﹤0.01%	4972
2020 Q2	$18K	Buy	+63	New	+$19.1K	﹤0.01%	5218
2020 Q1	–	Hold	0	–	–	–	6131
2019 Q4	–	Hold	0	–	–	–	6342
2019 Q3	–	Hold	0	–	–	–	6703
2019 Q2	–	Hold	0	–	–	–	6935
2019 Q1	–	Hold	0	–	–	–	7005
2018 Q4	–	Hold	0	–	–	–	6930
2018 Q3	–	Hold	0	–	–	–	7112
2018 Q2	–	Hold	0	–	–	–	6960
2018 Q1	–	Hold	0	–	–	–	7048
2017 Q4	–	Hold	0	–	–	–	6917

Other funds holding AYTU

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Crown Advisors Management Larkspur, California $182M AUM 103.97% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Barclays's AYTU Position: Q2 2026 in Review

Barclays opened a new position in AYTU BioPharma (AYTU) in Q2 2026: 50 shares worth $108. The stake represents ﹤0.01% of the portfolio and ranks #5187 among its holdings. This is a return to the name: Barclays previously reported a position in AYTU as recently as Q3 2025.

Barclays first reported a position in AYTU in Q2 2020 and has held it in 6 quarters since. The position peaked at $18K in Q2 2020. 38 funds tracked by Wall St. Rank hold AYTU as of Q2 2026.

Barclays held 50 shares of AYTU BioPharma worth $108 as of Q2 2026.
AYTU BioPharma was a new Barclays position in Q2 2026.
AYTU BioPharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5187 holding.
Barclays first reported a position in AYTU BioPharma in Q2 2020 and has held it in 6 quarters since.
Barclays's AYTU BioPharma position peaked at $18K in Q2 2020.
38 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.